Resource Summary

Clinical Question:
If non-valvular atrial fibrillation (AF) patients on warfarin require an interruption of warfarin^ should we offer bridging with a heparin product?

According to present evidence^ non-valvular AF patients on warfarin at lower risk of thromboembolism do not require bridging for brief interruptions ≤7 days (preferably ≤5 days). Bridging is still recommended in higher-risk (e.g. recent stroke/TIA^ mechanical valves^ rheumatic valve disease^ or CHADS2 score ≥3) and interruptions >7 days. See 2010 Canadian AF guidelines for specific recommendations on bridging.

*** Original Documents can be found and downloaded using the link provided below ***

Publication Date: 2013-10-28
Last Updated on PCR: 2017-03-31 15:11:49